RENB: Renovaro Inc. Price/Earnings to Growth Multiple
Renovaro Inc. bases its model on AI diagnostics for oncology and infections to provide accurate risk forecasting. The growth company undervaluation metric shows that the current level is around 0.00, attributing this to the development of innovative gene vaccines. However, the lack of stable operating cash flow and a reliance on investment capital make the asset high-risk during the clinical trial stage.
Metric breakdowns and analytics for Renovaro Inc. (RENB)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
Debt to Capital Renovaro Inc.|RENB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital renovarobio.com|RENB - Company Aggregate Debts|Debts to Book Value Enochian BioSciences|RENB - Company Long-Term Debt|Company Short-Term Indebtedness Renovaro|Immediate Liquidity renovarobio.com
- company profitability and valuation multiples indicators:
RENB - Net Income|Expected Profit Renovaro Inc.|RENB - P/E Multiple|Forward P/E Multiple renovarobio.com|RENB - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Enochian BioSciences|RENB - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Renovaro|RENB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months renovarobio.com|RENB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Renovaro Inc.
- total revenue and sales volume data:
General company analysis:RENB - Renovaro Biosciences
Assessing the market value of Renovaro Inc. (RENB) requires comparing the current P/E ratio with earnings dynamics. By analyzing the PEG ratio, an investor determines capitalization efficiency relative to business expansion rates. A value below one signals that the asset is undervalued. For the biotechnology sector and the development of immune platforms, this confirms growth potential through future drug sales. This indicator helps filter out random market volatility.
Competitors of Renovaro Inc.
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Ratio Delcath Systems, Inc. (DCTH)|YMAB (ymabs.com) - Growth-Adjusted Payback Ratio|PEG Multiple AURA (Aura Biosciences)|Candel Therapeutics Inc. (CADL) - Price to Earnings Adjusted for Growth Rate|ARAY - Price/Earnings to Growth Ratio|SLS (SELLAS Life Sciences) - Growth-Adjusted P/E Ratio|Actuate Therapeutics, Inc. (ACTU) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate citiusonc.com (CTOR)|Price/Earnings to Growth Multiple HURA|Price/Earnings to Growth Ratio TARA|PEG Multiple FATE|PEG Multiple aadibio.com (WHWK)|Price/Earnings to Growth Ratio TScan Therapeutics, Inc. TCRX|Growth-Adjusted Payback Ratio CSBR|XBIT - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate CEL-SCI Corporation|OSTX (OS Therapies Inc) - Price/Earnings to Growth Multiple|Radiopharm Theranostics Ltd - Growth-Adjusted Payback Ratio|ARTV (Artiva Biotherapeutics Inc.) - PEG Multiple|Adlai Nortye Limited (ANL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Veru (VERU)|Tempest Therapeutics Inc - Growth-Adjusted P/E Ratio|PEG Multiple XLO (Xilio Therapeutics)|MURA - Price/Earnings to Growth Multiple|KAPA: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income OnKure Therapeutics Inc OKUR|w2.cytomed.sg (GDTC) - Price/Earnings to Growth Ratio|Curis - Growth-Adjusted Payback Ratio|APLM (Apollomics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tharimmune Corporation THAR|Price/Earnings to Growth Ratio Advanced Biomed Inc (ADVB)|genprex.com - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|Sunshine Biopharma Inc. - Price/Earnings to Growth Ratio|Xenetic Bio - PEG Multiple|Salarius Pharma (SLRX) - Price/Earnings to Growth Multiple|PPBT: PEG Multiple|American Oncology Network, Inc. (AONC) - PEG Multiple|Price/Earnings to Growth Ratio BeiGene|Growth-Adjusted P/E Ratio CKPT (Checkpoint Therapeutics Inc.)|PEG Multiple ELEV|Price/Earnings to Growth Multiple icadmed.com ICAD|PEG Multiple IKNA (Ikena Oncology)|notablelabs.com (NTBL) - Price to Earnings Adjusted for Growth Rate|VIRX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA (NAYA Bio) - Price/Earnings to Growth Multiple|Ascentage - Growth-Adjusted Payback Ratio
